Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADM03820 Phase 1 study for COVID-19 prevention
NCT04592549Phase 1Completed
- Sponsor
- Resilience Government Services
- Start
- Dec 2020
- Primary completion
- Oct 2023
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ADM03820 in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Resilience Government Services. Primary endpoints: Number of Participants With Serious Adverse Events at 540 days, Number of Participants With Adverse Events at 540 days and 1 more. Started Dec 2020; status: completed.
02
Drugs
ADM03820
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04592549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04592549.